National Institute of Dental and Craniofacial Research (NIDCR)
nidcr.nih.govTotal trials
94
Active
13
Phase 3
3
Total enrollment
34,779
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| tofacitinib | — | — | — | — | — | 2 | |
| Denosumab | — | — | — | — | — | 2 | |
| PTH-IA | — | — | — | — | — | 1 | |
| Intrathecal Resiniferatoxin | — | — | — | — | — | 1 |
Next readouts
- 2021-11-17
- 2025-01-14
- 2027-02-07
- 2029-06-01
- 2030-12-15
Top conditions
- Healthy15
- Sjogren's Syndrome14
- Pain10
- Xerostomia6
- Polyostotic Fibrous Dysplasia5
- Salivary Gland Disease4
- Tooth Extraction4
- Dental Caries3
Frequently asked questions about National Institute of Dental and Craniofacial Research (NIDCR)
- How many clinical trials does National Institute of Dental and Craniofacial Research (NIDCR) have on ClinicalTrials.gov?
- National Institute of Dental and Craniofacial Research (NIDCR) is listed as the lead sponsor on 94 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Institute of Dental and Craniofacial Research (NIDCR)'s trials are in Phase 3?
- 3 of National Institute of Dental and Craniofacial Research (NIDCR)'s trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does National Institute of Dental and Craniofacial Research (NIDCR) focus on?
- National Institute of Dental and Craniofacial Research (NIDCR)'s most-studied conditions on ClinicalTrials.gov are Healthy, Sjogren's Syndrome, Pain, Xerostomia, Polyostotic Fibrous Dysplasia.
- When are National Institute of Dental and Craniofacial Research (NIDCR)'s next clinical trial readouts?
- National Institute of Dental and Craniofacial Research (NIDCR) has 5 upcoming primary-completion readouts tracked here; the soonest is “Denosumab Treatment for Fibrous Dysplasia”, expected around 2021-11-17.